Mesenchymal Stromal Cells
History
WJ-MSCs, cells at the heart of StemInov’s innovation, are a particular type of adult MSC, of which several types have been described according to their location in the body and their origin in foetal (Wharton’s jelly) or adult tissues (two main sources are bone marrow (BM), adipose tissue (AT)).
Thanks to their properties (figure below) Mesenchymal stem cells (MSCs) are a critical raw material for many regenerative medicine products, including cell-based therapies, engineered tissues, or combination products. Indeed, MSCs modulate the host immune systems, e.g., by secreting various trophic factors. Thereby, they reduce inflammation, promote neoangiogenesis, and prevent apoptosis and fibrosis. Additionally, they stimulate local stem cells to develop new tissue.
Furthermore, as they do not express major histocompatibility complex (MHC) class II molecules and have only low levels of MHC class I, MSCs are poorly immunogenic cells and therefore potentially usable in an allogeneic situation (where the donor is a different person from the patient), which makes them particularly attractive for clinical use.
Properties
WJ-MSCs have intrinsic properties that hold great promise for the treatment of infectious and inflammatory diseases, including septic shock. Indeed, these cells have a triple mechanism of action:
- Unique modulation of immunity and inflammation through pro- or anti-inflammatory behavior depending on the environment in which they are located,
- Direct and indirect antibacterial by effect on phagocytic cells capable of eliminating the pathogenic microorganisms responsible for the infection,
- Targeting and migrating to injured sites for tissue repair.
The Mesenchymal Stromal Cells (MSC) field is a validated and de-risked therapeutic modality…
1990s
MSC first clinical trials
2024
First US MSC approval (Ryoncil®,)
2025+
Commercial ramp-up
$4B
Global MSC market, 2025
13%
CAGR (2026–2035)²
First approved MSC therapy
Ryoncil (Mesoblast) — steroid-refractory acute GvHD,· ~$120M FY2026 sales
2 approved MSC products
North America / EU
Ryoncil · Holoclar
10 locally approved MSC products
Asia & emerging markets
Late-stage (Phase III) programs
- Mesoblast — chronic low back pain / heart failure
- Stempeutics — diabetic foot ulcer
- Medipost — knee cartilage defects
- Mesoblast — acute GvHD
Cell sources¹

Treatment type¹

¹ Source: Mab Design external study – on data room
² Source: Grand View Research 2023
StemInov selected Wharton’s jelly as its cell source, as it outperforms other MSC sources
Umbilical cord
Bone marrow or adipose tissueComplex & invasive sampling
Umbilical cord
Bone marrow or adipose tissueLack of homogeneity between samples (age of the donor)
Umbilical cord
Bone marrow or adipose tissue++
Umbilical cord
Bone marrow or adipose tissueYES
Umbilical cord
Bone marrow or adipose tissue+
Umbilical cord
WhartSep® mechanism of action is based on three main actions
Manage & modulate inflammation
Modulate pro-inflammatory cytokines and promote secretion of anti-inflammatory cytokines
—
Balance innate and adaptive immunity
Lower the infective load
Enhance bacterial clearance by producing antimicrobial peptides
—
Cell-to-cell contact boosts monocyte and alveolar macrophage phagocytosis, without excessive inflammation
Protect the lungs
Restore alveolar epithelial fluid clearance
—
Protect endothelial barriers
—
Mitigate vascular permeability and edema
Partners
R&D


Support



Labels



